Analysis of expression and prognosis of KLK7 in ovarian cancer

Chen, Erhua; Zhu, Hui; Yang, Yong; Zhang, Jianhua; Han, Yonghong; Liu, Xiang

doi:10.1515/med-2020-0139

Cited by 6 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies show that KLK 7 levels are significantly higher in the two types of ovarian cancer-serous and endometrial. This has been associated with worse FPS in patients [38]. In addition, KLK7 overexpression has been found to induce chemo-resistance and increase levels of alpha5/beta1 integrins, which induce ovarian cell invasion thereby increasing spread to the peritoneum and reinvasion [39].…”

Section: Kallikreinsmentioning

confidence: 99%

The latest reports on biomarkers used in the diagnosis of ovarian cancer

Chałupnik

Chilimoniuk

Dobosz

et al. 2022

J Educ Health Sport

View full text Add to dashboard Cite

Introduction: Ovarian cancer ranks seventh in terms of incidence and eighth in terms of mortality among women worldwide. It is divided into several subtypes. The epithelial type of ovarian cancer is responsible for 90% of cases. The clinical picture is usually an appendage tumor detected by palpation or during pelvic imaging. Symptoms are usually non-specific such as abdominal pushing or bloating. State of knowledge: Ovarian cancer is usually detected at an advanced stage due to the long duration of absence of symptoms. Therefore, there is an urgent need to look at existing and identify potential biomarkers that can lead to the development of new and more effective predictors for the diagnosis and prognosis of ovarian cancer. The ability of these biomarkers to predict the existence and stages of ovarian cancer could improve early diagnosis and survival of ovarian cancer patients. Currently, the biomarkers CA-125 and HE4 play the most important role in diagnosis. However, there are an increasing number of reports on other biomarkers such as kallikreins, bikunin, VEGF, and mesothelin. Summary: Partly due to the lack of effective screening, ovarian cancer is usually diagnosed in the final stages. This is why ongoing research into new biomarkers that could contribute to faster detection of the disease is so important. They would also increase the effectiveness of the therapies used and enable a better prognosis of the course of the disease.

show abstract

Section: Kallikreinsmentioning

confidence: 99%

The latest reports on biomarkers used in the diagnosis of ovarian cancer

Chałupnik

Chilimoniuk

Dobosz

et al. 2022

J Educ Health Sport

View full text Add to dashboard Cite

show abstract

“…On the other hand, KLK7 displays aberrant expression in cancer, in particular, pancreatic adenocarcinomas 10 and may promote pancreatic cancer by cleaving the intercellular adhesion protein desmoglein 2 11 or by inducing E-cadherin shedding. 10 KLK7 is also overexpressed in ovarian cancer, 12 and it is considered to promote ovarian cancer by activating matrix metalloproteinases and via induction of IGF signaling following degradation of IGFBPs by KLK7. 13 Recently, KLK7 was shown to attenuate the symptoms of Alzheimer's disease in vivo .…”

Section: Introductionmentioning

confidence: 99%